No. of isolates | Unadjusted | Adjusted by age, sex and areas | ||||
---|---|---|---|---|---|---|
Total | Clustered (%) | OR* | 95 % CI* | OR* | 95 % CI* | |
Socio and clinical factors | ||||||
Sex | ||||||
Female | 33 | 7 (21.2) | 1 | 1 | ||
Male | 101 | 26 (25.7) | 1.29 | 0.469–3.931 | 1.20 | 0.435–4.041 |
Treatment episode | ||||||
=2 | 76 | 13 (17.1) | 1 | 1 | ||
≥3 | 58 | 20 (34.5) | 2.55 | 1.060–6.238** | 2.41 | 1.012–6.543** |
Sputum smear | ||||||
Negative | 9 | 2 (22.2) | 1 | 1 | ||
Positive | 125 | 31 (24.8) | 1.15 | 0.205–11.94 | 1.12 | 0.201–12.02 |
Drug resistance and genetic mutation: | ||||||
Other DR | 60 | 9 (15.0) | 1 | 1 | ||
MDR | 70 | 24 (34.3) | 2.45 | 1.008–6.363** | 2.43 | 1.007–6.471** |
preXDR/XDR | 25 | 6 (24.0) | 1.79 | 0.456–6.520 | 1.81 | 0.451–6.522 |
Drug resistant isolates with mutation in: | ||||||
WT | 38 | 7 (18.4) | 1 | 1 | ||
katG | 59 | 12 (20.3) | 1.33 | 0.421–4.470 | 1.28 | 0.419–4.451 |
rpoB | 55 | 21 (38.2) | 2.74 | 0.943–8.622 | 2.64 | 0.873–8.953 |
pncA | 39 | 8 (20.5) | 1.14 | 0.317–4.197 | 1.15 | 0.313–4.221 |
gyrA | 11 | 3 (27.3) | 1.66 | 0.224–9.531 | 1.53 | 0.214–9.524 |
rrs | 7 | 1 (14.3) | 0.74 | 0.014–7.907 | 0.71 | 0.010–8.123 |
eis | 4 | 0 (0) | - | - |